__________________________________________________________________________________________
05/JUN/2014
Re: Local ID TH140202165/ TH201402006303 FU (2)
Thank you for reporting to us a serious adverse event related to Lilly product.
We would like to collect more information to better understanding the reported event.
Please respond to following questions regarding the adverse event – Death involving a female patient, who was subscribed Forteo, reported the event to Lilly on 19/FEB/2014.
Please try to obtain the following information from HCP, if possible:
1. What was basis for patient's history of immunecompromise ?
___________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
2. Indication for prednisolone?
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
3. Was a source or cause of sepsis determined? If so, please provide relevant clinical and diagnostic findings obtained to support diagnosis.
____________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________
Thanks
Yours sincerely,
ELI LILLY AND COMPANY
Sasithorn Suntharo
Pharmacovigilance Associate
HCP’s signature:
Date:
__________________________________________________________________________________
For Eli Lilly internal use only
Date of Confirmation of FU request sent to HCP:
Name and Designation: